Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of GZR18 Tablet in Healthy Chinese Adults
NCT06554054Phase 1Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bofanglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Adverse Events at 35 days, Serious Adverse Events at 35 days and 3 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06554054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554054.